TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02025140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer controlled anesthesia
Description: The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer controlled anesthesia
Description: The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia syringe
Description: Active control
Study: NCT04444193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
Study: NCT01797861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Half-dose photodynamic therapy (PDT)
Description: At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse laser (ML) treatment
Description: The following ML treatment settings will be used: a power of 1800 mW\*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~\* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area.
Study: NCT02365389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTZ vaginal gel
Description: MTZ vaginal gel once daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional MTZ vaginal gel
Description: Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
Study: NCT03927521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance
Description: Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
Study: NCT01800643

Intervention type: OTHER
Group type: OTHER
Intervention: Analyze the pharmacokinetics of busulfan for transplantation
Description: Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target.

Intervention type: OTHER
Group type: OTHER
Intervention: Analyze the pharmacokinetics of busulfan for transplantation
Description: Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target.
Study: NCT04762615

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH level measurement
Description: AMH level measurement using ELISA test from blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH level measurement
Description: AMH level measurement using ELISA test from blood samples

Intervention type: DIAGNOSTIC_TEST
Intervention: AMH level measurement
Description: AMH level measurement using ELISA test from blood samples
Study: NCT01443221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitiglinide and metformin
Description: Free combination of Mitiglinide 10mg and Metformin 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitiglinide and metformin
Description: Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
Study: NCT04590911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enrichment Program (CEP)
Description: Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
Study: NCT02073825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Brief Intervention (WBI)
Description: 4-session WBI
Study: NCT02865070

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor

Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor
Study: NCT01974700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
Study: NCT02907814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Exam
Description: This is a brief, non-contact ocular exam.
Study: NCT02624739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
Study: NCT02699879

Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone will be administered according to the physician discretion as part of standard care.
Study: NCT02822625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QUTENZA®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QUTENZA®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypnotic message

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy
Study: NCT04186845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study: NCT01018225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darifenacin
Description: 7.5 or 15 mg darifenacin, once a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, once a day, for six weeks
Study: NCT02090634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized Texting for Adherence Building (iTAB)
Description: Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
Study: NCT01706302

Intervention type: OTHER
Intervention: Data collection
Description: The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
Study: NCT03120754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Place the peritoneal drainage
Description: In the experimental group, the abdominal drainage was not placed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No peritoneal drainage
Description: Intraoperative placement of peritoneal drainage as control group.
Study: NCT04166825

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.
Study: NCT03266614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery 4 Us
Description: R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
Study: NCT02260076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04236258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
Study: NCT03329937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
Study: NCT00449280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg BID (200 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg BID (200 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg BID (200 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg BID (200 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 30mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 30mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 3mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 3mg once daily
Study: NCT01747590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02427711

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar sealer
Description: Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bipolar sealer
Description: Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
Study: NCT06763185

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption
Description: Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption
Description: Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
Study: NCT03927261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-3006 T Cells
Description: Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
Study: NCT02093897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Study: NCT03265847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-tailored Safety Planning
Description: The intervention will provide safety planning/referrals tailored to the DA
Study: NCT03937921

Intervention type: DRUG
Intervention: Gadavist 15Ml Solution for Injection
Description: Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
Study: NCT00491985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split-virion pandemic influenza vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split virion pandemic influenza vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split virion pandemic influenza vaccine
Description: 0.25 mL, Intramuscular
Study: NCT04159974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/ML
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/ML
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV Infusion, Combination with Durvalumab
Study: NCT05877443

Intervention type: PROCEDURE
Intervention: Open system
Description: Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask

Intervention type: PROCEDURE
Intervention: Non-invasive mechanical ventilation
Description: Respiratory support by for example continues or bilevel positive airway pressure

Intervention type: PROCEDURE
Intervention: Invasive mechanical ventilation
Description: Respiratory support delivered through endotracheal tube or tracheostomy
Study: NCT01641263

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Therapy
Description: Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitve Behavioral Therapy for Insomnia
Description: For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
Study: NCT02178059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate delivered dose
Description: 0.4 mg terbutaline sulphate (delivered dose) per inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline sulphate metered dose
Description: 0.5 mg terbutaline sulphate (metered dose) per inhalation
Study: NCT02198495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of ferric carboxymaltose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of iron sucrose
Study: NCT00437645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules
Study: NCT02782390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Restoration with Stainless Crown
Description: Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Restoration with Composite Resin
Description: Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions.
Study: NCT00605202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg a day for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: Licorice candy 32 grams a day for 14 days.
Study: NCT03586583

Intervention type: DEVICE
Intervention: FBP
Description: Old processing

Intervention type: DEVICE
Intervention: ISR
Description: New processing
Study: NCT01756664

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Study: NCT00823784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal doppler hemorrhoidal ligation
Description: THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled hemorrhoidopexy
Description: Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture